Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer
Joshua K. Sabari, Vamsidhar Velcheti, K. Shimizu, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 15, pp. 3318-3328
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Pasi A. Jänne, Gregory J. Riely, Shirish M. Gadgeel, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 2, pp. 120-131
Open Access | Times Cited: 581
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 126
Drugging KRAS: current perspectives and state-of-art review
Kaushal Parikh, Giuseppe Luigi Banna, Stephen V. Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 83
Adagrasib: First Approval
Sohita Dhillon
Drugs (2023) Vol. 83, Iss. 3, pp. 275-285
Closed Access | Times Cited: 82
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 74
Emerging evidence and treatment paradigm of non-small cell lung cancer
Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 56
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases
Marcelo V. Negrão, Alexander I. Spira, Rebecca S. Heist, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 28, pp. 4472-4477
Open Access | Times Cited: 39
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
Mariacarmela Santarpía, Giuliana Ciappina, Calogera Claudia Spagnolo, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 2, pp. 346-368
Open Access | Times Cited: 29
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
James Cregg, Kristóf Póta, Aidan C.A. Tomlinson, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Martin Sattler, Atish Mohanty, Prakash Kulkarni, et al.
Trends in cancer (2022) Vol. 9, Iss. 1, pp. 42-54
Open Access | Times Cited: 28
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer
Kelsey Pan, Kyle Concannon, Jing Li, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 716-732
Closed Access | Times Cited: 20
D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity
Zhe Shi, Jifang Weng, Haotao Niu, et al.
Cancer Science (2023) Vol. 114, Iss. 7, pp. 2951-2960
Open Access | Times Cited: 15
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Fernand Bteich, Mahshid Mohammadi, T. Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12030-12030
Open Access | Times Cited: 14
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
Judit Moldvay, József Tı́már
Pathology & Oncology Research (2024) Vol. 29
Open Access | Times Cited: 5
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Jing Zhang, Sun Min Lim, Mi Ra Yu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 9, pp. 1675-1698
Open Access | Times Cited: 5
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
Danielle Brazel, Misako Nagasaka
Targeted Oncology (2024) Vol. 19, Iss. 3, pp. 297-301
Open Access | Times Cited: 5
Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine
İbrahim Halil Şahin, Turçin Saridogan, Rüveyda Ayasun, et al.
JCO Oncology Practice (2024) Vol. 20, Iss. 10, pp. 1336-1347
Closed Access | Times Cited: 5
KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
Linyan Tian, Chengming Liu, Sufei Zheng, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
Cancer brain metastasis: molecular mechanisms and therapeutic strategies
Yucheng Lu, Ying Huang, Cuiqing Zhu, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access
Post-marketing safety of Adagrasib: a disproportionality analysis based on the FAERS database
Zheng Shi, Yu Xia, Yifan Zhao, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
The epigenetic landscape of brain metastasis
Aoibhín M. Powell, L. Watson, L Luzietti, et al.
Oncogene (2025)
Open Access
Contract to kill: GNAS mutation
Pratima Raut, Poompozhil Mathivanan, Surinder K. Batra, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Recent advances in therapeutic strategies for non-small cell lung cancer
Po‐Lan Su, Naoki Furuya, Atif Asrar, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top